Robin Jones, MD, The Royal Marsden Hospital, London, UK, comments on the potential of artificial intelligence (AI) in refining the diagnosis of sarcomas and developing precision therapeutics. Prof. Jones notes that AI holds great promise, but significant research is needed to develop reliable tools for diagnosing rare sarcoma subtypes, and to better guide therapy selection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.